Salt Lake City, Utah
Cancer clinical trials in Salt Lake City, UT
174 cancer studies are recruiting participants at sites in Salt Lake City as of November 16, 2026, according to ClinicalTrials.gov. Oncology Research Hub can help you understand your options and connect with a study team.
- No cost to ask
- Taking part is voluntary
- Studies are independently reviewed
Salt Lake City at a glance
- 174 studies are recruiting at a site in Salt Lake City.
- By phase: Early Phase 1 (2), Phase 1 (25), Phase 1/2 (31), Phase 2 (36), Phase 2/3 (5), Phase 3 (48), No phase (16), Observational (11). Studies of devices and behavioral approaches have no phase.
- By sponsor: university, hospital or other (84), industry (77), government (13).
- By research area: Lymphoma (60), Breast Cancer (42), Lung Cancer (29), Melanoma (16), Prostate Cancer (15), Pancreatic Cancer (12).
- Most recent update to one of these records: November 16, 2026.
Breast cancer studies recruiting in Salt Lake City
Basic details from each study's public record (the 30 most recently updated of 174). Select a study to read the full record on ClinicalTrials.gov, including how to contact its team.
A Study of ASP546C in Adults With Gastroesophageal Cancer, Pancreatic Cancer or Other Solid Tumors
- Phase 1/2
- Ages 18 and older
- All sexes
- Sponsor
- Astellas Pharma Global Development, Inc.
- Study site
- Huntsman Cancer Institute University of Utah
- Registry record
- NCT07488676 · updated
A Study of Sacituzumab Tirumotecan (Sac-TMT, MK-2870) as Monotherapy and in Combination With Pembrolizumab (MK-3475) in Participants With Triple-Negative Breast Cancer (MK-2870-011/TroFuse-011)
- Phase 3
- Ages 18 and older
- All sexes
- Sponsor
- Merck Sharp & Dohme LLC
- Study site
- University of Utah, Huntsman Cancer Institute ( Site 0056)
- Registry record
- NCT06841354 · updated
A Study With NKT3964 for Adults With Advanced/Metastatic Solid Tumors
- Phase 1
- Ages 19 and older
- All sexes
- Sponsor
- NiKang Therapeutics, Inc.
- Study site
- Intermountain Health
- Registry record
- NCT06586957 · updated
Phase 3 Study of RLY-2608 + Fulvestrant vs Capivasertib + Fulvestrant as Treatment for Locally Advanced or Metastatic PIK3CA-mutant HR+/HER2- Breast Cancer
- Phase 3
- Ages 18 and older
- All sexes
- Sponsor
- Relay Therapeutics, Inc.
- Study site
- Huntsman Cancer Institute, University of Utah
- Registry record
- NCT06982521 · updated
Study of Sacituzumab Govitecan-hziy and Pembrolizumab Versus Treatment of Physician's Choice in Patients With Triple Negative Breast Cancer Who Have Residual Invasive Disease After Surgery and Neoadjuvant Therapy (ASCENT-05/AFT-65 OptimICE-RD/GBG 119/NSABP B-63)
- Phase 3
- Ages 18 and older
- All sexes
- Sponsor
- Gilead Sciences
- Study site
- Huntsman Cancer Institute
- Registry record
- NCT05633654 · updated
Evaluating the Addition of Adjuvant Chemotherapy to Ovarian Function Suppression Plus Endocrine Therapy in Premenopausal Patients With pN0-1, ER-Positive/HER2-Negative Breast Cancer and an Oncotype Recurrence Score Less Than or Equal to 25
- Phase 3
- Ages 18 to 60
- Female participants
- Sponsor
- NRG Oncology
- Study sites
- Huntsman Cancer Institute/University of Utah · University of Utah Sugarhouse Health Center
- Registry record
- NCT05879926 · updated
Source: ClinicalTrials.gov. Data processed . See every breast cancer study recruiting in Salt Lake City, UT on ClinicalTrials.gov.
Lung cancer studies recruiting in Salt Lake City
A Study to Compare the Combination of Navlimetostat (BMS-986504) With Pembrolizumab and Chemotherapy Versus Placebo Plus Pembrolizumab and Chemotherapy in First-line Metastatic Non-small Cell Lung Cancer Participants With Homozygous MTAP Deletion
- Phase 2/3
- Ages 18 and older
- All sexes
- Sponsor
- Bristol-Myers Squibb
- Study site
- Huntsman Cancer Institute
- Registry record
- NCT07063745 · updated
A Phase 2 Study of VS-7375 in Patients With KRAS G12D-Mutated Non-Small Cell Lung Cancer
- Phase 2
- Ages 18 and older
- All sexes
- Sponsor
- Verastem, Inc.
- Study site
- University of Utah
- Registry record
- NCT07659782 · updated
Testing Lutetium Lu 177 Dotatate in Patients With Somatostatin Receptor Positive Advanced Bronchial Neuroendocrine Tumors
- Phase 2
- Ages 18 and older
- All sexes
- Sponsor
- National Cancer Institute (NCI)
- Study site
- Huntsman Cancer Institute/University of Utah
- Registry record
- NCT04665739 · updated
A Phase 1 Dose Escalation and Dose Expansion Trial of KST-6051 in Participants With Advanced Solid Tumors With Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) Mutation
- Phase 1
- Ages 18 and older
- All sexes
- Sponsor
- Kestrel Therapeutics, Inc.
- Study site
- Huntsman Cancer Institute, University of Utah
- Registry record
- NCT07458347 · updated
A Study to Assess Efficacy and Safety of Pembrolizumab With or Without Sacituzumab Tirumotecan (MK- 2870) in Adult Participants With Resectable Non Small Cell Lung Cancer (NSCLC) Not Achieving Pathological Complete Response (pCR) (MK-2870-019)
- Phase 3
- Ages 18 and older
- All sexes
- Sponsor
- Merck Sharp & Dohme LLC
- Study site
- Huntsman Cancer Institute ( Site 0042)
- Registry record
- NCT06312137 · updated
A Phase 1/2 Study of VS-7375 in Patients With KRAS G12D-Mutated Solid Tumors
- Phase 1/2
- Ages 18 and older
- All sexes
- Sponsor
- Verastem, Inc.
- Study site
- Huntsman Cancer Institute
- Registry record
- NCT07020221 · updated
Source: ClinicalTrials.gov. Data processed . See every lung cancer study recruiting in Salt Lake City, UT on ClinicalTrials.gov.
Prostate cancer studies recruiting in Salt Lake City
TulmiSTAR-02: A Phase I/II Open-label Study of Tulmimetostat in Combination With Darolutamide vs. Darolutamide, and Tulmimetostat With Abiraterone in Patients With Metastatic Hormone-sensitive Prostate Cancer (mHSPC)
- Phase 1/2
- Ages 18 and older
- Male participants
- Sponsor
- Novartis Pharmaceuticals
- Study site
- Huntsman Cancer Institute
- Registry record
- NCT07190300 · updated
Optimal PSA Triggered Individual Management of Androgen Sensitive Prostate Cancer
- Phase 2
- Ages 18 and older
- Male participants
- Sponsor
- University of Utah
- Study site
- Huntsman Cancer Institute at University of Utah
- Registry record
- NCT07216248 · updated
Source: ClinicalTrials.gov. Data processed . See every prostate cancer study recruiting in Salt Lake City, UT on ClinicalTrials.gov.
Melanoma studies recruiting in Salt Lake City
Effects of Nicotinamide in Patients With Chronic Lymphocytic Leukemia With History of Non-melanoma Skin Cancers
- Phase 2
- Ages 18 and older
- All sexes
- Sponsor
- University of Utah
- Study site
- Huntsman Cancer Institute at University of Utah
- Registry record
- NCT04844528 · updated
BiCaZO: A Study Combining Two Immunotherapies (Cabozantinib and Nivolumab) to Treat Patients With Advanced Melanoma or Squamous Cell Head and Neck Cancer, an immunoMATCH Pilot Study
- Phase 2
- Ages 18 and older
- All sexes
- Sponsor
- National Cancer Institute (NCI)
- Study site
- Huntsman Cancer Institute/University of Utah
- Registry record
- NCT05136196 · updated
A Study With Combinations of Anti-LAG-3 and Anti-PD-1 Antibodies in Adult Participants With Advanced or Metastatic Melanoma (Harmony Head-to-Head)
- Phase 3
- Ages 18 and older
- All sexes
- Sponsor
- Regeneron Pharmaceuticals
- Study site
- University of Utah Huntsman Cancer Institute
- Registry record
- NCT06246916 · updated
Source: ClinicalTrials.gov. Data processed . See every melanoma study recruiting in Salt Lake City, UT on ClinicalTrials.gov.
Lymphoma studies recruiting in Salt Lake City
A Multicenter Study to Evaluate Next-Generation Sequencing (NGS) Testing and Monitoring of B-Cell Recovery to Guide Management Following Chimeric Antigen Receptor T-cell (CART) Induced Remission in Children and Young Adults With B Lineage Acute Lymph...
- No phase
- Ages 1 to 25
- All sexes
- Sponsor
- National Cancer Institute (NCI)
- Study site
- Huntsman Cancer Institute, University of Utah
- Registry record
- NCT05621291 · updated
Testing Whether High Dose Chemotherapy and Infusion of the Patients' Own Stem Cells Improves Survival in Patients With Peripheral T-cell Lymphoma Who Achieved a Complete Response at the End of the Initial Chemotherapy
- Phase 3
- Ages 18 to 75
- All sexes
- Sponsor
- Eastern Cooperative Oncology Group
- Study site
- Huntsman Cancer Institute/University of Utah
- Registry record
- NCT06724237 · updated
A Study of NX-5948 in Adults With CLL/SLL Previously Treated With a Bruton's Tyrosine Kinase Inhibitor and a B-cell Lymphoma-2 Inhibitor (DAYBreak CLL-201)
- Phase 2
- Ages 18 and older
- All sexes
- Sponsor
- Nurix Therapeutics, Inc.
- Study site
- University of Utah
- Registry record
- NCT07221500 · updated
A Study of CD19 Targeted CAR T Cell Therapy in Pediatric Patients With Relapsed or Refractory B Cell Acute Lymphoblastic Leukemia (B ALL) and Aggressive Mature B-cell Non-Hodgkin Lymphoma (B NHL)
- Phase 1
- Ages 0 to 18
- All sexes
- Sponsor
- Autolus Limited
- Study site
- Primary Children's Hospital
- Registry record
- NCT06173518 · updated
Testing Early Treatment for Patients With High-Risk Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Leukemia (SLL), EVOLVE CLL/SLL Study
- Phase 3
- Ages 18 and older
- All sexes
- Sponsor
- National Cancer Institute (NCI)
- Study site
- Huntsman Cancer Institute/University of Utah
- Registry record
- NCT04269902 · updated
A Study to Compare Blinatumomab Alone to Blinatumomab With Nivolumab in Patients Diagnosed With First Relapse B-Cell Acute Lymphoblastic Leukemia (B-ALL)
- Phase 2
- Ages 1 to 30
- All sexes
- Sponsor
- National Cancer Institute (NCI)
- Study site
- Primary Children's Hospital
- Registry record
- NCT04546399 · updated
A Study to Compare Standard Therapy to Treat Hodgkin Lymphoma to the Use of Two Drugs, Brentuximab Vedotin and Nivolumab
- Phase 3
- Ages 5 to 60
- All sexes
- Sponsor
- National Cancer Institute (NCI)
- Study sites
- Huntsman Cancer Institute/University of Utah · Primary Children's Hospital
- Registry record
- NCT05675410 · updated
TINI 2: Total Therapy for Infants With Acute Lymphoblastic Leukemia II
- Phase 1/2
- Up to age 1
- All sexes
- Sponsor
- Tanja Andrea Gruber
- Study site
- University of Utah Huntsman Cancer Institute
- Registry record
- NCT05848687 · updated
A Trial to Learn if Odronextamab is Safe and Well-Tolerated and How Well it Works Compared to Rituximab Combined With Different Types of Chemotherapy for Adult Participants With Previously Untreated Follicular Lymphoma
- Phase 3
- Ages 18 and older
- All sexes
- Sponsor
- Regeneron Pharmaceuticals
- Study site
- Huntsman Cancer Institute - Oncology Division
- Registry record
- NCT06091254 · updated
Comparing Rituximab and Mosunetuzumab Drug Treatments for People With Low Tumor Burden Follicular Lymphoma
- Phase 3
- Ages 18 and older
- All sexes
- Sponsor
- National Cancer Institute (NCI)
- Study site
- Huntsman Cancer Institute/University of Utah
- Registry record
- NCT06337318 · updated
A Study Evaluating the Safety, Efficacy, and Pharmacokinetics of Mosunetuzumab and a Combined Regimen of Mosunetuzumab and Venetoclax in Participants With Relapsed or Refractory Chronic Lymphocytic Leukemia
- Phase 1
- Ages 18 and older
- All sexes
- Sponsor
- Hoffmann-La Roche
- Study site
- Huntsman Cancer Institute at The University of Utah
- Registry record
- NCT05091424 · updated
Source: ClinicalTrials.gov. Data processed . See every lymphoma study recruiting in Salt Lake City, UT on ClinicalTrials.gov.
Pancreatic cancer studies recruiting in Salt Lake City
A Study to Evaluate Chemotherapy With or Without INCB161734 in Previously Untreated, KRAS G12D-Mutated Metastatic Pancreatic Ductal Adenocarcinoma
- Phase 3
- Ages 18 and older
- All sexes
- Sponsor
- Incyte Corporation
- Study site
- Investigative Site US053
- Registry record
- NCT07522073 · updated
APOLLO: A Randomized Phase II Double-Blind Study of Olaparib Versus Placebo Following Curative Intent Therapy in Patients With Resected Pancreatic Cancer and a Pathogenic BRCA1, BRCA2 or PALB2 Mutation
- Phase 2
- Ages 18 and older
- All sexes
- Sponsor
- National Cancer Institute (NCI)
- Study sites
- Huntsman Cancer Institute/University of Utah · University of Utah Sugarhouse Health Center
- Registry record
- NCT04858334 · updated
Source: ClinicalTrials.gov. Data processed . See every pancreatic cancer study recruiting in Salt Lake City, UT on ClinicalTrials.gov.
Ask about studies near Salt Lake City
Tell us what you are looking for and a coordinator will contact you to talk through your options. Asking does not commit you to anything.
Before you contact a study
How taking part works
From your first question to your decision: what happens and who you talk to along the way.
Questions to ask a study team
What to ask about time, risks and your rights before you agree to anything.
Eligibility and screening
How a study team works out whether a study is suitable for you.
About these listings
These listings come from ClinicalTrials.gov, the study registry run by the U.S. National Library of Medicine. The data were processed on November 16, 2026. We show part of each public record (its title, phase, sponsor, basic eligibility and sites in this area) exactly as registered, and we group studies by place. Nothing in a record is reworded.
Oncology Research Hub does not run these studies and is not affiliated with their sponsors. A listing is not a recommendation, and only a study's own team can tell you whether you may be eligible. Follow the link on any study to read its full record and contact that team directly, or ask us and a coordinator will help you understand your options. How we source and check what we publish.
Sources and further reading
- ClinicalTrials.gov study registry — ClinicalTrials.gov (National Library of Medicine)
- Terms and Conditions for use of ClinicalTrials.gov data — ClinicalTrials.gov (National Library of Medicine)
- Questions to Ask About Volunteering for a Research Study — HHS Office for Human Research Protections